Overview
- The BMJ study published on Wednesday, July 22 analysed about 50,000 Penn Medicine records and found GLP‑1 receptor agonist users had a 37% higher adjusted risk of clinically recorded alopecia versus SGLT‑2 users and a 68% higher risk versus DPP‑4 users.
- The absolute risk was low in the study, roughly 3 to 9 new cases of alopecia per 1,000 people per year, so only a small share of patients on GLP‑1 drugs experienced clinically recorded hair loss.
- Regulators in the UK and the US have received hundreds of spontaneous reports and are actively evaluating the safety signal, and some product labels now note alopecia as a possible adverse reaction.
- Further analyses showed the effect was mainly non‑scarring alopecia, which often allows regrowth, and researchers say the most plausible pathway is telogen effluvium caused by rapid weight loss or deficiencies in iron, zinc or biotin.
- Clinicians are urged to counsel patients about the small risk, monitor nutritional status during rapid weight loss, and researchers call for peer‑reviewed mechanistic studies and clearer comparisons between drugs such as tirzepatide and semaglutide.